Biotech Values

[jaybe]

Do PD-L1 populations overlap EGFRm in NSCLC?


PD-L1/PD-1 immunotherapy is coming to NSCLC, but the question arises will it take market share from known driver mutations such as EGFRm (15% ADC) or ALK (5% ADC), or is the PD-L1/PD-1 population (50% NSCLC) substantially independent, i.e. consisting mostly of the 45% driver-unknown population? Two studies below suggest conflicting answers:

No correlation view
insert-text-here

Strong correlation view
insert-text-here